Business
Cytek Biosciences Reports First Quarter 2025 Financial Results
FREMONT, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the first quarter ended March 31, 2025. First Quarter Highlights Total revenue for the first quarter of 2025 was $41.5 million, representing a 7.6% decrease compared to the first quarter of 2024Expanded to a total installed base of 3,149 Cytek instruments, including the Amnis® and Guava® instrum
About this update from Cytek Biosciences, Inc.
[{"type":"image","alt":"Cytek Biosciences, Inc.","displaySize":"","headline":null,"caption":"Cytek Biosciences, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":94,"url":"https://media.zenfs.com/en/globenewswire.com/bc3b354d3f50b53d40b4edfe89e7fd8f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/3p0SVRz3IvMSXP918Y7IYw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzMjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/bc3b354d3f50b53d40b4edfe89e7fd8f","width":300,"height":94}},"lazy":false},{"type":"text","content":"FREMONT, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the first quarter ended March 31, 2025.","length":248,"tagName":"p"},{"type":"text","content":"First Quarter Highlights","length":24,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Total revenue for the first quarter of 2025 was $41.5 million, representing a 7.6% decrease compared to the first quarter of 2024","length":129,"tagName":"p"}]},{"val":[{"type":"text","content":"Expanded to a total installed base of 3,149 Cytek instruments, including the Amnis® and Guava® instruments shipped since the acquisition of the product lines in February 2023, adding 115 units in the first quarter of 2025","length":221,"tagName":"p"}]},{"val":[{"type":"text","content":"Commenced operations in Singapore to access low-cost manufacturing, increase capacity and enhance global supply flexibility","length":123,"tagName":"p"}]},{"val":[{"type":"text","content":"Launched the Cytek Muse® Micro instrument, a next-gen cell analyzer that is an affordable option for simplified flow cytometry while enhancing ease-of-use, precision and versatility","length":181,"tagName":"p"}]},{"val":[{"type":"text","content":"Repurchased $10.6 million of Cytek common stock in open market purchases during the first quarter of 2025","length":105,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":759,"olType":false},{"type":"text","content":"“I am encouraged by the resilience of our portfolio amidst a challenging macroeconomic backdrop, exemplified by double-digit revenue growth in Cytek cell sorters and our service business, and strength in the APAC region,” said Dr. Wenbin Jiang CEO of Cytek Bioscience. “We ...